Christian Brun-Buisson
Research Subjects
Research Interests
Christian Brun-Buisson has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Arnaud Wilfrid Thille
Service de Médecine Intensive Réanimation, CHU de Poitiers, Poitiers, France
5 shared publications - Keyvan Razazi
Henri-Mondor Hospital, Créteil, France
4 shared publications - Armand Mekontso Dessap
Hôpital Henri-Mondor
3 shared publications - Florence Boissier
CHU de Poitiers, Médecine Intensive Réanimation, Poitiers, France.
3 shared publications - Ana Córdoba-Izquierdo
AP-HP, Réanimation Médicale, Groupe Hospitalier Henri Mondor - Albert Chenevier, Créteil, France
2 shared publications - Anne-Marie Dupuy
Laboratoire de Biochimie et Hormonologie, CHU Montpellier, Univ Montpellier 1, Montpellier, F-34295, cédex 5, France
2 shared publications
Latest Publications
- Open Access
- 26 February 2016
- Published by Springer Nature in Critical Care
- Vol. 20 (1) , 1-8
Easily identified at-risk patients for extubation failure may benefit from noninvasive ventilation: a prospective before-after study
Background: While studies have suggested that prophylactic noninvasive ventilation (NIV) could prevent post-extubation respiratory failure in the intensive care unit, they appear inconsistent with regard to reintubation. We assessed the impact of a prophylactic NIV protocol on reintubation in a large population of at-risk patients. Methods: Prospective before-after study performed in the medical ICU of a teaching referral hospital. In the control cohort, we determined that patients older than 65 years and those with underlying cardiac or respiratory disease were at high-risk for reintubation. In the interventional cohort, we implemented a protocol using prophylactic NIV in all patients intubated at least 24 h and having one of these risk factors. NIV was immediately applied after planned extubation during at least the first 24 hours. Extubation failure was defined by the need for reintubation within seven days following extubation. Results: We included 83 patients at high-risk among 132 extubated patients in the control cohort (12-month period) and 150 patients at high-risk among 225 extubated patients in the NIV cohort (18-month period). The reintubation rate was significantly decreased from 28 % in the control cohort (23/83) to 15 % (23/150) in the NIV cohort (p = 0.02 log-rank test), whereas the non-at-risk patients did not significantly differ in the two periods (10.2 % vs. 10.7 %, p = 0.93). After multivariate logistic-regression analysis, the use of prophylactic NIV protocol was independently associated with extubation success. Conclusions: The implementation of prophylactic NIV after extubation may reduce the reintubation rate in a large population of patients with easily identified risk factors for extubation failure.
- 26 February 2016
- Published by Springer Nature in Critical Care
- Vol. 20 (1) , 1-8
Open AccessEasily identified at-risk patients for extubation failure may benefit from noninvasive ventilation: a prospective before-after study
Background: While studies have suggested that prophylactic noninvasive ventilation (NIV) could prevent post-extubation respiratory failure in the intensive care unit, they appear inconsistent with regard to reintubation. We assessed the impact of a prophylactic NIV protocol on reintubation in a large population of at-risk patients. Methods: Prospective before-after study performed in the medical ICU of a teaching referral hospital. In the control cohort, we determined that patients older than 65 years and those with underlying cardiac or respiratory disease were at high-risk for reintubation. In the interventional cohort, we implemented a protocol using prophylactic NIV in all patients intubated at least 24 h and having one of these risk factors. NIV was immediately applied after planned extubation during at least the first 24 hours. Extubation failure was defined by the need for reintubation within seven days following extubation. Results: We included 83 patients at high-risk among 132 extubated patients in the control cohort (12-month period) and 150 patients at high-risk among 225 extubated patients in the NIV cohort (18-month period). The reintubation rate was significantly decreased from 28 % in the control cohort (23/83) to 15 % (23/150) in the NIV cohort (p = 0.02 log-rank test), whereas the non-at-risk patients did not significantly differ in the two periods (10.2 % vs. 10.7 %, p = 0.93). After multivariate logistic-regression analysis, the use of prophylactic NIV protocol was independently associated with extubation success. Conclusions: The implementation of prophylactic NIV after extubation may reduce the reintubation rate in a large population of patients with easily identified risk factors for extubation failure.
- Open Access
- 1 June 2015
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (6) , 1979-1982
Severe Ketoalkalosis as Initial Presentation of Imported Human Rabies in France
We report a patient with an unusual initial metabolic presentation of imported human rabies, who became symptomatic within two weeks of returning from Mali. This is the single case of imported human rabies identified in France within the past 11 years, and the first report of viral RNA in bronchial secretions.
- 1 June 2015
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (6) , 1979-1982
Open AccessSevere Ketoalkalosis as Initial Presentation of Imported Human Rabies in France
We report a patient with an unusual initial metabolic presentation of imported human rabies, who became symptomatic within two weeks of returning from Mali. This is the single case of imported human rabies identified in France within the past 11 years, and the first report of viral RNA in bronchial secretions.
- Open Access
- 1 January 2015
- Published by Elsevier in Annals of Intensive Care
- Vol. 5 (1) , 14
Severe but not mild hypercapnia affects the outcome in patients with severe cardiogenic pulmonary edema treated by non-invasive ventilation
- 1 January 2015
- Published by Elsevier in Annals of Intensive Care
- Vol. 5 (1) , 14
Open AccessSevere but not mild hypercapnia affects the outcome in patients with severe cardiogenic pulmonary edema treated by non-invasive ventilation
- Open Access
- 1 January 2015
- Published by Elsevier in Annals of Intensive Care
- Vol. 5 (1) , 1-9
Echocardiographic detection of transpulmonary bubble transit during acute respiratory distress syndrome
- 1 January 2015
- Published by Elsevier in Annals of Intensive Care
- Vol. 5 (1) , 1-9
Open AccessEchocardiographic detection of transpulmonary bubble transit during acute respiratory distress syndrome
- 17 December 2014
- Published by Lavoisier in Réanimation
- Vol. 24 (S2) , 304-314
Le dépistage des porteurs de bactéries multirésistantes : chez quels patients ?
Le dépistage des bactéries multirésistantes (BMR) en réanimation fait l’objet de controverses persistantes, ravivées par l’arrivée de nouvelles menaces. Les recommandations disponibles sont discordantes. L’attitude vis-à-vis des BMR endémiques, en pratique le staphylocoque doré résistant à la méticilline (SARM) et les entérobactéries productrices de bêtalactamases à spectre élargi (EBLSE), est de privilégier les précautions standard, de manière adaptée à l’épidémiologie de chacune des BMR concernées : hygiène des mains et décolonisation éventuelles des porteurs pour SARM, et attention particulière à la gestion des excréta pour EBLSE. Le dépistage (associé à l’isolement) des porteurs de ces BMR n’apporte pas de bénéfice par rapport à une bonne application des précautions standard. Le dépistage est en revanche justifié pour la maîtrise de la transmission croisée des BMR hautement résistantes émergentes (BHRe), c’est-à-dire en France les entérobactéries productrices de carbapénémases et les entérocoques résistants aux glycopeptides ainsi qu’en situation endémo-épidémique ou épidémique pour les autres BMR, notamment des EBLSE autres qu’E. coli. En réanimation, les Acinetobacter résistant aux carbapénèmes doivent être pris en charge de la même manière que les BHRe. Le volet complémentaire indispensable à la maîtrise de la diffusion hospitalière des BMR, notamment pour les bacilles à gram négatif, est l’usage prudent et raisonné des antibiotiques. Active surveillance screening (ASC) of patients hospitalized in intensive care units (ICU) or elsewhere searching for carriers of multidrug-resistant bacteria (MDRB) remains controversial. Available guidelines are discordant. Current French recommendations emphasize standard precautions as the principal control measure against endemic MDRB, complemented by specific measures according to the epidemiology of each species, i.e., possible decontamination of methicillin-resistant Staphylococcus aureus (MRSA) carriers, and special attention to the handling of secretions and excreta for the extended-spectrum beta-lactamase producing enterobacteriaceae (ESBL-PE). In the current endemic setting which prevails in most European countries, screening and isolation of carriers of these two MDRB has no added benefit over optimal observance of standard precautions, in the absence of outbreak. Conversely, ASC is justified for the control of outbreaks and control of the highly-resistant bacteria which have recently emerged, and are still rarely encountered in most settings. In France, these highly-resistant bacteria include carbapenem-resistant enterobacteriaceae and glycopeptide-resistant enterococci. Carbapenem-resistant Acinetobacter warrant the same approach in the ICU. Infection control efforts to prevent cross-transmission must be complemented by a strict antimicrobial stewardship for optimal effectiveness of the control program.
- 17 December 2014
- Published by Lavoisier in Réanimation
- Vol. 24 (S2) , 304-314
Le dépistage des porteurs de bactéries multirésistantes : chez quels patients ?
Le dépistage des bactéries multirésistantes (BMR) en réanimation fait l’objet de controverses persistantes, ravivées par l’arrivée de nouvelles menaces. Les recommandations disponibles sont discordantes. L’attitude vis-à-vis des BMR endémiques, en pratique le staphylocoque doré résistant à la méticilline (SARM) et les entérobactéries productrices de bêtalactamases à spectre élargi (EBLSE), est de privilégier les précautions standard, de manière adaptée à l’épidémiologie de chacune des BMR concernées : hygiène des mains et décolonisation éventuelles des porteurs pour SARM, et attention particulière à la gestion des excréta pour EBLSE. Le dépistage (associé à l’isolement) des porteurs de ces BMR n’apporte pas de bénéfice par rapport à une bonne application des précautions standard. Le dépistage est en revanche justifié pour la maîtrise de la transmission croisée des BMR hautement résistantes émergentes (BHRe), c’est-à-dire en France les entérobactéries productrices de carbapénémases et les entérocoques résistants aux glycopeptides ainsi qu’en situation endémo-épidémique ou épidémique pour les autres BMR, notamment des EBLSE autres qu’E. coli. En réanimation, les Acinetobacter résistant aux carbapénèmes doivent être pris en charge de la même manière que les BHRe. Le volet complémentaire indispensable à la maîtrise de la diffusion hospitalière des BMR, notamment pour les bacilles à gram négatif, est l’usage prudent et raisonné des antibiotiques. Active surveillance screening (ASC) of patients hospitalized in intensive care units (ICU) or elsewhere searching for carriers of multidrug-resistant bacteria (MDRB) remains controversial. Available guidelines are discordant. Current French recommendations emphasize standard precautions as the principal control measure against endemic MDRB, complemented by specific measures according to the epidemiology of each species, i.e., possible decontamination of methicillin-resistant Staphylococcus aureus (MRSA) carriers, and special attention to the handling of secretions and excreta for the extended-spectrum beta-lactamase producing enterobacteriaceae (ESBL-PE). In the current endemic setting which prevails in most European countries, screening and isolation of carriers of these two MDRB has no added benefit over optimal observance of standard precautions, in the absence of outbreak. Conversely, ASC is justified for the control of outbreaks and control of the highly-resistant bacteria which have recently emerged, and are still rarely encountered in most settings. In France, these highly-resistant bacteria include carbapenem-resistant enterobacteriaceae and glycopeptide-resistant enterococci. Carbapenem-resistant Acinetobacter warrant the same approach in the ICU. Infection control efforts to prevent cross-transmission must be complemented by a strict antimicrobial stewardship for optimal effectiveness of the control program.
- Open Access
- 31 October 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (5) , 613
Minimizing antibiotic exposure in the ICU: in search of the optimal strategy
The current paradigm for antibiotic management in critically ill patients is to initiate broad-spectrum therapy followed by de-escalation based on microbiological results. Routine screening cultures may allow better targeting and reduce unnecessary exposure to antibiotics.
- 31 October 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (5) , 613
Open AccessMinimizing antibiotic exposure in the ICU: in search of the optimal strategy
The current paradigm for antibiotic management in critically ill patients is to initiate broad-spectrum therapy followed by de-escalation based on microbiological results. Routine screening cultures may allow better targeting and reduce unnecessary exposure to antibiotics.
- 24 March 2014
- Published by Lavoisier in Réanimation
- Vol. 23 (3) , 278-283
Désescalade de l’antibiothérapie en réanimation
Une antibiothérapie initiale précoce et efficace, souvent large, associée au contrôle de la source de l’infection reste la pierre angulaire du traitement des sepsis. Cependant, une antibiothérapie à large spectre a un impact négatif sur l’écologie microbienne individuelle et collective. Ce dilemme des réanimateurs face aux infections graves peut être résolu par une stratégie de désescalade précoce. La désescalade permet une diminution de l’exposition aux antibiotiques par réduction de durée (allant jusqu’à l’arrêt précoce du traitement antimicrobien), par la diminution du nombre de molécules administrées et/ou la substitution de molécule en réduisant le spectre d’activité d’une antibiothérapie probabiliste à large spectre. Elle est possible dans 20 à 50 % des cas selon les pratiques empiriques et le contexte épidémiologique. Elle peut être envisagée dès la 24e heure, mais surtout à 48–72 heures après réception des résultats de prélèvements microbiologiques considérés fiables. Par extension, l’antibiothérapie doit être réévaluée tous les jours de même que l’on réévalue quotidiennement la sédation d’un patient ventilé. Cette stratégie n’est pas délétère, et certaines données récentes suggèrent même un effet protecteur sur l’apparition d’infections nosocomiales ainsi que sur la mortalité. Successful treatment of severe infections in the intensive care unit (ICU) often requires broad-spectrum empiric therapy, while attempting to control the source of infection. However, this liberal antibiotic strategy may be associated with adverse effects on the patients as well as on the overall microbial ecology of the unit. This “antibiotic dilemma” may be solved by early de-escalation of antibiotic therapy, which allows reducing the overall antibiotic exposure of ICU patients by shortening the duration of therapy (including early stop when infection is not confirmed), switching from combined to single therapy, and/or substituting broad-spectrum agent with narrower-spectrum regimen. The opportunity for de-escalation varies across series from 20% to 50%, depending on the empiric antibiotic policy and the epidemiological context. Adapting the antibiotic regimen, possible as early as 24 h after obtaining the first results from adequate samples, is mandatory at 48–72 h, once full microbiological results are obtained. Subsequently, the intensivist must reassess daily the continued need for antibiotics, just like sedation is reassessed daily in mechanically ventilated patients. Several studies have confirmed that early deescalation is safe, and recent evidence suggests that it may even be associated with improved outcome of patients.
- 24 March 2014
- Published by Lavoisier in Réanimation
- Vol. 23 (3) , 278-283
Désescalade de l’antibiothérapie en réanimation
Une antibiothérapie initiale précoce et efficace, souvent large, associée au contrôle de la source de l’infection reste la pierre angulaire du traitement des sepsis. Cependant, une antibiothérapie à large spectre a un impact négatif sur l’écologie microbienne individuelle et collective. Ce dilemme des réanimateurs face aux infections graves peut être résolu par une stratégie de désescalade précoce. La désescalade permet une diminution de l’exposition aux antibiotiques par réduction de durée (allant jusqu’à l’arrêt précoce du traitement antimicrobien), par la diminution du nombre de molécules administrées et/ou la substitution de molécule en réduisant le spectre d’activité d’une antibiothérapie probabiliste à large spectre. Elle est possible dans 20 à 50 % des cas selon les pratiques empiriques et le contexte épidémiologique. Elle peut être envisagée dès la 24e heure, mais surtout à 48–72 heures après réception des résultats de prélèvements microbiologiques considérés fiables. Par extension, l’antibiothérapie doit être réévaluée tous les jours de même que l’on réévalue quotidiennement la sédation d’un patient ventilé. Cette stratégie n’est pas délétère, et certaines données récentes suggèrent même un effet protecteur sur l’apparition d’infections nosocomiales ainsi que sur la mortalité. Successful treatment of severe infections in the intensive care unit (ICU) often requires broad-spectrum empiric therapy, while attempting to control the source of infection. However, this liberal antibiotic strategy may be associated with adverse effects on the patients as well as on the overall microbial ecology of the unit. This “antibiotic dilemma” may be solved by early de-escalation of antibiotic therapy, which allows reducing the overall antibiotic exposure of ICU patients by shortening the duration of therapy (including early stop when infection is not confirmed), switching from combined to single therapy, and/or substituting broad-spectrum agent with narrower-spectrum regimen. The opportunity for de-escalation varies across series from 20% to 50%, depending on the empiric antibiotic policy and the epidemiological context. Adapting the antibiotic regimen, possible as early as 24 h after obtaining the first results from adequate samples, is mandatory at 48–72 h, once full microbiological results are obtained. Subsequently, the intensivist must reassess daily the continued need for antibiotics, just like sedation is reassessed daily in mechanically ventilated patients. Several studies have confirmed that early deescalation is safe, and recent evidence suggests that it may even be associated with improved outcome of patients.
- 18 March 2014
- Published by Springer Nature in Intensive Care Medicine
- Vol. 40 (4) , 600-602
Healthcare-associated pneumonia: another nail in the coffin?
- 18 March 2014
- Published by Springer Nature in Intensive Care Medicine
- Vol. 40 (4) , 600-602
Healthcare-associated pneumonia: another nail in the coffin?
- Open Access
- 10 March 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (2) , R44
Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis
Introduction: Procalcitonin (PCT) is helpful for diagnosing bacterial infections. The diagnostic utility of PCT has not been examined thoroughly in critically ill patients with suspected H1N1 influenza. Methods: Clinical characteristics and PCT were prospectively assessed in 46 patients with pneumonia admitted to medical ICUs during the 2009 and 2010 influenza seasons. An individual patient data meta-analysis was performed by combining our data with data from five other studies on the diagnostic utility of PCT in ICU patients with suspected 2009 pandemic influenza A(H1N1) virus infection identified by performing a systematic literature search. Results: PCT levels, measured within 24 hours of ICU admission, were significantly elevated in patients with bacterial pneumonia (isolated or coinfection with H1N1; n = 77) (median = 6.2 μg/L, interquartile range (IQR) = 0.9 to 20) than in patients with isolated H1N1 influenza pneumonia (n = 84; median = 0.56 μg/L, IQR = 0.18 to 3.33). The area under the curve of the receiver operating characteristic curve of PCT was 0.72 (95% confidence interval (CI) = 0.64 to 0.80; P < 0.0001) for diagnosis of bacterial pneumonia, but increased to 0.76 (95% CI = 0.68 to 0.85; P < 0.0001) when patients with hospital-acquired pneumonia and immune-compromising disorders were excluded. PCT at a cut-off of 0.5 μg/L had a sensitivity (95% CI) and a negative predictive value of 80.5% (69.9 to 88.7) and 73.2% (59.7 to 84.2) for diagnosis of bacterial pneumonia, respectively, which increased to 85.5% (73.3 to 93.5) and 82.2% (68.0 to 92.0) in patients without hospital acquired pneumonia or immune-compromising disorder. Conclusions: In critically ill patients with pneumonia during the influenza season, PCT is a reasonably accurate marker for detection of bacterial pneumonia, particularly in patients with community-acquired disease and without immune-compromising disorders, but it might not be sufficient as a stand-alone marker for withholding antibiotic treatment.
- 10 March 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (2) , R44
Open AccessProcalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis
Introduction: Procalcitonin (PCT) is helpful for diagnosing bacterial infections. The diagnostic utility of PCT has not been examined thoroughly in critically ill patients with suspected H1N1 influenza. Methods: Clinical characteristics and PCT were prospectively assessed in 46 patients with pneumonia admitted to medical ICUs during the 2009 and 2010 influenza seasons. An individual patient data meta-analysis was performed by combining our data with data from five other studies on the diagnostic utility of PCT in ICU patients with suspected 2009 pandemic influenza A(H1N1) virus infection identified by performing a systematic literature search. Results: PCT levels, measured within 24 hours of ICU admission, were significantly elevated in patients with bacterial pneumonia (isolated or coinfection with H1N1; n = 77) (median = 6.2 μg/L, interquartile range (IQR) = 0.9 to 20) than in patients with isolated H1N1 influenza pneumonia (n = 84; median = 0.56 μg/L, IQR = 0.18 to 3.33). The area under the curve of the receiver operating characteristic curve of PCT was 0.72 (95% confidence interval (CI) = 0.64 to 0.80; P < 0.0001) for diagnosis of bacterial pneumonia, but increased to 0.76 (95% CI = 0.68 to 0.85; P < 0.0001) when patients with hospital-acquired pneumonia and immune-compromising disorders were excluded. PCT at a cut-off of 0.5 μg/L had a sensitivity (95% CI) and a negative predictive value of 80.5% (69.9 to 88.7) and 73.2% (59.7 to 84.2) for diagnosis of bacterial pneumonia, respectively, which increased to 85.5% (73.3 to 93.5) and 82.2% (68.0 to 92.0) in patients without hospital acquired pneumonia or immune-compromising disorder. Conclusions: In critically ill patients with pneumonia during the influenza season, PCT is a reasonably accurate marker for detection of bacterial pneumonia, particularly in patients with community-acquired disease and without immune-compromising disorders, but it might not be sufficient as a stand-alone marker for withholding antibiotic treatment.
- 1 January 2014
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 23 (1) , 84-85
Incidence of shoulder injuries after generalized tonic–clonic seizure admitted to intensive care
- 1 January 2014
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 23 (1) , 84-85
Incidence of shoulder injuries after generalized tonic–clonic seizure admitted to intensive care